Real world outcomes of patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated in 1l with lenvatinib 24 mg: an international multicenter real-world study in europe and canada
Key Points
Key points are not available for this paper at this time.
Abstract
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
Demander à l'IA
Like
Bookmark
Share
Demander à l'IA
Like
Bookmark
Share
Real world outcomes of patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated in 1l with lenvatinib 24 mg: an international multicenter real-world study in europe and canada | Synapse